Evidence map›Paper›PMID 30865050›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2019

The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.

Elizabeth T Montgomery, Millicent Atujuna, Emily Krogstad, Miriam Hartmann, Sheily Ndwayana, Shannon OʼRourke, Linda-Gail Bekker, Ariane van der Straten, Alexandra M Minnis

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elizabeth T MontgomeryWomen's Global Health Imperative, Center for Global Health/SSES, RTI International, San Francisco Project Office, San Francisco, CA.
Millicent AtujunaDesmond Tutu HIV Research Centre, Cape Town, South Africa.
Emily KrogstadWomen's Global Health Imperative, Center for Global Health/SSES, RTI International, San Francisco Project Office, San Francisco, CA.
Miriam HartmannWomen's Global Health Imperative, Center for Global Health/SSES, RTI International, San Francisco Project Office, San Francisco, CA.
Sheily NdwayanaDesmond Tutu HIV Research Centre, Cape Town, South Africa.
Shannon OʼRourkeWomen's Global Health Imperative, Center for Global Health/SSES, RTI International, San Francisco Project Office, San Francisco, CA.
Linda-Gail BekkerDesmond Tutu HIV Research Centre, Cape Town, South Africa.
Ariane van der StratenWomen's Global Health Imperative, Center for Global Health/SSES, RTI International, San Francisco Project Office, San Francisco, CA.
Alexandra M MinnisWomen's Global Health Imperative, Center for Global Health/SSES, RTI International, San Francisco Project Office, San Francisco, CA.

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
End-user research to optimize adherence to injectable HIV prevention approachesR01MH105262 · NIMH · RESEARCH TRIANGLE INSTITUTE · PI MONTGOMERY, ELIZABETH TRASK · 2015 to 2017
$1.8M
NIMH NIH HHS P30 MH062246NIMH NIH HHS R01 MH105262
6 · The paper itself

Abstract

backgroundLong-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches.

methodsNinety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience.

resultsIrrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods.

conclusionsNarrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact.

Indexed as

Patient PreferenceAdolescentAnti-HIV AgentsDelayed-Action PreparationsFemaleHIV InfectionsHumansInterviews as TopicMalePre-Exposure ProphylaxisSouth AfricaYoung AdultAnti-HIV AgentsDelayed-Action Preparations

Identifiers

PMID30865050
PMCPMC6426447

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.